Clinical-stage drug development company Nyrada (ASX:NYR) has released its half-year results for the 2026 fiscal year, headlined by the completion of Phase 1 clinical trials for its lead drug candidate, Xolatryp.
The trial data confirmed a robust safety profile with no serious adverse events or dose-limiting safety signals, demonstrating predictable, linear pharmacokinetics in human participants.
Following the positive results, the company has received HREC approval to advance to a Phase 2a clinical trial targeting STEMI (heart attack) patients undergoing primary PCI, with patient recruitment slated to begin in March.
Nyrada is expanding Xolatryp’s therapeutic reach. Preclinical animal studies have been initiated to evaluate the drug’s efficacy in oncological indications.
Collaborative research with UNSW Sydney and the Walter Reed Army Institute of Research has validated Xolatryp's ability to reduce mitochondrial calcium loading in the brain—a critical discovery that reinforces its potential for protecting against both brain and cardiac injuries.
The period also marked a significant leadership transition, with CEO James Bonnar joining the board following the retirement of Gisela Mautner, signaling a streamlined focus as the company enters its next phase of clinical validation.
At the time of reporting, Nyrada's share price was $0.69.